Business context and reporting period
Koninklijke Philips N.V. filed this Form 20-F on February 21, 2023, reporting for the fiscal year ended December 31, 2022. Philips is a Netherlands-based health technology company with Diagnosis & Treatment, Connected Care, Personal Health and Other reporting segments. The filing provides annual results, not standalone fourth-quarter financial statements; clear Q4-only values are not provided in the supplied text. Financial statements are prepared under IFRS.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Sales | €17.827 billion; nominal growth 3.9%, comparable sales decline 2.8% | €17.156 billion; comparable sales decline 1.2% |
| Gross margin | €7.194 billion; 40.4% of sales | €7.168 billion; 41.8% of sales |
| Income from operations | Loss of €1.529 billion; (8.6)% of sales | Income of €553 million; 3.2% of sales |
| Net income | Loss of €1.605 billion | Income of €3.323 billion |
| Adjusted EBITA | €1.318 billion; 7.4% of sales | €2.054 billion; 12.0% of sales |
| Operating cash flow | Outflow of €173 million | Inflow of €1.629 billion |
| Free cash flow | Outflow of €961 million | Inflow of €900 million |
| Cash and cash equivalents | €1.172 billion | €2.303 billion |
| Total debt / net debt | €8.201 billion / €7.028 billion | €6.980 billion / €4.676 billion |
| Inventories | €4.049 billion | €3.450 billion |
Management’s non-IFRS measures, including Adjusted EBITA and free cash flow, should be considered alongside the comparable IFRS measures and may not be comparable with similarly named measures at other companies.
Accessible liquidity at year-end was €2.704 billion, including cash, a €1 billion committed revolving credit facility and €500 million of undrawn capacity under a separate €1 billion facility. Philips had drawn €500 million on that separate facility. It reported no commercial paper outstanding. In 2022, Philips issued €2 billion of bonds and undertook liability management that reduced scheduled debt repayments for 2023–2025 from €3.2 billion to €2.0 billion.
Segment performance: Diagnosis & Treatment sales were €9.168 billion (comparable decline 0.7%) and Adjusted EBITA margin was 8.4%; Connected Care sales were €4.403 billion (decline 10.8%) and margin was 2.2%; Personal Health sales were €3.626 billion (growth 0.1%) and margin was 14.8%.
Material changes versus the prior comparable period
- Comparable sales fell 2.8%, with Connected Care down 10.8%, primarily reflecting the Respironics field action and supply constraints. Diagnosis & Treatment declined 0.7%; Personal Health was approximately flat.
- Adjusted EBITA fell to €1.318 billion from €2.054 billion, as lower sales and inflationary costs outweighed pricing and productivity measures. Gross margin declined 1.4 percentage points.
- The net loss chiefly reflected €1.357 billion of goodwill impairments and other impairment and restructuring charges. The comparison was also affected by the €2.5 billion after-tax gain on the Domestic Appliances sale in 2021.
- Operating cash flow swung to an outflow, attributed to lower cash earnings, increased working capital and cash costs related to the Respironics field action. Supply shortages contributed to higher inventory, especially work in process.
- Net debt increased by €2.352 billion year over year, while cash declined by €1.131 billion.
Outlook, commentary, risks and unusual items
Management gave no specific numerical 2023 sales or margin guidance in the supplied filing text. It described its outlook as cautious, citing subdued economic conditions, customer staffing and inflation pressures, geopolitical risks, supply-and-demand volatility, and uncertainty around the proposed Respironics consent decree, litigation and Department of Justice investigations. Its stated priorities are patient safety and quality, supply-chain reliability, a simpler operating model, focused organic growth and disciplined capital allocation.
- Respironics recall: By year-end, about 90% of production required for replacement-device deliveries had been completed. Philips estimated around 5.6 million devices would require remediation. The year-end field-action provision was €390 million; the company also incurred €210 million of running remediation costs. Consent-decree discussions with US authorities remained ongoing. The provision excludes product-liability costs and other claims; the company said it could not reliably estimate the potential obligations from related litigation.
- Testing and legal exposure: Management reported encouraging results for first-generation DreamStation devices, representing over two-thirds of affected registered devices, but testing across device categories was ongoing. The filing describes consumer class actions, hundreds of individual US personal-injury complaints, investigations and other claims.
- Other investigations: Philips recorded a €60 million provision for public investigations into alleged tender irregularities involving Brazil, China and Bulgaria, while stating that it could not reliably estimate the full financial effect of possible outcomes.
- Restructuring: Following a 4,000-role reduction announced in 2022, Philips announced a further 6,000-role reduction by 2025, including 3,000 in 2023. Approximately €470 million of charges were expected in 2023 for the additional measures.
- Dividend: Management proposed a dividend of €0.85 per share, payable in shares, subject to shareholder approval. The stated policy targets dividend stability and a 40%–50% payout of adjusted continuing-operations income when applicable.
- Other financial items: The effective tax rate was 6.5%, and continuing operations recorded a €113 million income tax benefit. Goodwill impairment assumptions for Sleep & Respiratory Care remain sensitive to sales growth, discount rates and the scope and duration of a potential consent decree.
The independent auditor issued unqualified opinions on the IFRS financial statements and internal control over financial reporting. Management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2022.
Important facts for investors to verify
- Progress and cost to complete the Respironics repair-and-replacement program, remaining testing, and the final terms and financial effects of any consent decree.
- Developments in Respironics litigation and investigations, including whether provisions or cash requirements change as claims progress.
- Whether supply constraints ease, inventories convert into sales, and order-book strength translates into revenue and cash flow.
- Recovery in Connected Care and improvement in group margins, while tracking the effect of inflation, pricing and productivity initiatives.
- Execution, timing and cash costs of the announced workforce reductions and other restructuring measures.
- Liquidity, debt maturities, credit ratings and cash generation, including the impact of the proposed share dividend and capital allocation.